

Jul 10th, 2015

**Notification of the commencement of the Phase II / III clinical study of HP-3150 in Japan
(an analgesic transdermal drug containing NSAIDs)**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hiroataka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces that it has commenced of the Phase II / III clinical study in Japan for an analgesic transdermal patch containing NSAIDs (Development code: HP-3150, hereinafter referred to as “the product”).

The product is a systemic transdermal drug developed utilizing Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology and containing the active ingredient NSAIDs (Non-Steroidal Anti-Inflammatory Drugs).

In the Phase II / III clinical study, the efficacy and safety of administration of the product will be compared with a placebo in patients suffering from cancer pain. We expect the product to be a new option for the treatment of such patients who will benefit from its long-lasting effect by means of maintaining a stable blood concentration.

We aim to apply for manufacturing and marketing approval during FY 2016.